US Medical Innovations has recently announced that it is developing the first robotic delivery system for cancer surgery. The robot is called the Canady Surgical System (CSS) and consists of Voice Command Technology and includes Canady Hybrid Plasma™ (CHP) and Canady Helios™ Cold Atmospheric Plasma (CHCAP) and disposable cameras and scopes.
The robot looks to allow surgeons to focus on other surgical tasks as the robot fulfills tasks that require better mobility and directed treatments. The robot utilizes an image-guided navigational mapping system that enables it to a ablate any remaining cancer cells once the tumor is removed.
This machine saves space and reduces costs during open, mini-invasive endoscopic, thoracoscopic, and trans-oral surgical procedures. It is also preloaded with treatment dosage protocols for more than 30 cancer types.
MD and CEO Jerome Canady said, “Our CHCAP technology actually ablates cancer cells without damaging surrounding healthy tissue. We recently completed a Phase 1 FDA Clinical Trail using Canady Helios™ Cold Atmospheric Plasma (CHCAP) for the treatment of recurrent and stage 4 solid tumors. We see this novel technology, delivered with the precision of robotic assisted technology, as the most exciting new form of personalized and targeted medicine being explored today.”
The CHCAP treatment is also personalized for cancer types such as breast, ovarian, sarcoma, lung, colon, cervical, pancreas, and more solid cancerous tumors. USMI’s robot only targets cancerous cells, meaning there is no damage to healthy cells.
There are many benefits to robotic surgery including greater mobility, allowing surgeons to operate on difficult locations in the body, and to free up the surgeon to perform other tasks, which also brings down the time spent on a procedure. USMI looks to have the Canady Surgical System in clinical trials later in 2021. At this time protocols and site locations are still being decided.